# Tiziana Life Sciences Completes Phase 2 Alzheimer's Trial Enrollment

- URL: https://stocks.freetheai.org/news/tiziana-life-sciences-completes-phase-2-alzheimer-s-trial-enrollment-96ac99
- Published: 2026-10-16T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:TLSA](https://stocks.freetheai.org/symbols/NASDAQ-TLSA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Tiziana Life Sciences Ltd. (TLSA) has reached full enrollment in its Phase 2 clinical trial evaluating intranasal foralumab for patients with early and mild Alzheimer's disease. The final patient in the study has started dosing, marking the completion of patient recruitment for the mid-stage study.

The trial tests foralumab both as a standalone treatment and in combination with existing therapies, specifically lecanemab and donanemab. Researchers are measuring key trial outcomes using cognitive assessments and TSPO-PET imaging, an objective biomarker designed to evaluate neuroinflammation in the brain.

With enrollment now closed, the program shifts focus toward data collection and readout. Topline results from the Phase 2 study are expected in the first quarter of 2027.

## Key points

- Tiziana Life Sciences completed patient enrollment for its Phase 2 trial of intranasal foralumab in early and mild Alzheimer's disease.
- The study evaluates foralumab as both a monotherapy and in combination with lecanemab or donanemab.
- Trial endpoints include cognitive measures and TSPO-PET brain imaging to evaluate neuroinflammation.
- Topline clinical data from the trial are expected in the first quarter of 2027.

## Questions and answers

### When will Tiziana Life Sciences report Phase 2 data for foralumab?

Tiziana Life Sciences expects to report topline data from its Phase 2 Alzheimer's disease trial in the first quarter of 2027.

### What is Tiziana Life Sciences testing in its Phase 2 Alzheimer's trial?

The Phase 2 study is testing intranasal foralumab both as a standalone treatment and in combination with lecanemab or donanemab for patients with early and mild Alzheimer's disease.

### What endpoints are being measured in the foralumab Phase 2 study?

The study endpoints include cognitive measures and TSPO-PET brain imaging to track neuroinflammation.